| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_fdaa64756184e715af6cb25ebc318917
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d202adb979a3d3f2fc9eb6922867d6ae
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d5781aecdd91930b1b7ee21bc4258b8b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b47a0c7e7e3e493eb5bb11fc7082dc11 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-555
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-54
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-642 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-48 |
| filingDate |
2001-10-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5fd824bbfb597bbc19c33d8cf0149870
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_29b7d34e93713249aa3f4cfc30c43277
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_29a3e0ce630d59aea5b51622fb99f683 |
| publicationDate |
2002-05-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-0236067-A2 |
| titleOfInvention |
Long-acting cytokine derivatives and pharmaceutical compositions comprising them |
| abstract |
Cytokine derivatives are provided bearing functional groups sensitive to mild basic conditions such as fluorenylmethoxycarbonyl (Fmoc) and 2-sulfo-9-fluorenylmethoxycarbonyl (FMS) and pharmaceutical compositions comprising them. Preferred derivates are those in which amino groups of the cytokine are substituted with FMS, for example FMS7-IFN-α2 and FMS3-IL-2. These cytokine derivatives can be administered as inactive or slightly active prodrugs and are capable of undergoing spontaneous regeneration into the parent bioactive drugs under in vivo physiological conditions and in a homegenous fashion. The cytokine prodrugs present higher metabolic stability and augmented bioavailability. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11266742-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8435505-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8703115-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10695435-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8252275-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-106554296-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9821070-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8911718-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10537646-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9090740-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10130720-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1620118-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2279758-A3
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9775911-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1620118-A4
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10166295-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9381254-B2 |
| priorityDate |
2000-11-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |